EBAC

KYG3167F1028

Market Closed - Nasdaq Other stock markets 21:30:01 17/05/2024 BST			5-day change	1st Jan Change
11.98 ^USD	+0.04%		-0.79%	+7.02%

2023	European Biotech Acquisition Corp.(NasdaqCM:EBAC) dropped from NASDAQ Composite Index	CI
2023	Oculis SA completed the acquition of European Biotech Acquisition Corp. from Lsp Sponsor Ebac B.V. and others in a reverse merger.	CI

European Biotech Acquisition Corp.(NasdaqCM:EBAC) added to NASDAQ Composite Index

May 19, 2021 at 05:00 am

European Biotech Acquisition Corp. has been added to NASDAQ Composite Index .

Latest news about EURO BIOT

European Biotech Acquisition Corp.(NasdaqCM:EBAC) dropped from NASDAQ Composite Index	02/03/23	CI
Oculis SA completed the acquition of European Biotech Acquisition Corp. from Lsp Sponsor Ebac B.V. and others in a reverse merger.	01/03/23	CI
European Biotech Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	28/02/23	CI
European Biotech Acquisition Corp. Auditor Raises 'Going Concern' Doubt	27/02/23	CI
European Biotech Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
European Biotech Acquisition, Oculis Strike Merger Agreement	17/10/22	MT
Oculis SA entered into a Business Combination Agreement to acquire European Biotech Acquisition Corp. from Lsp Sponsor Ebac B.V. in a reverse merger for approximately $210 million.	16/10/22	CI
European Biotech Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22	CI
European Biotech Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22	CI
European Biotech Acquisition Corp. Auditor Raises 'Going Concern' Doubt	30/03/22	CI
Certain Class B Ordinary Shares of European Biotech Acquisition Corp. are subject to a Lock-Up Agreement Ending on 15-SEP-2021.	14/09/21	CI
European Biotech Acquisition Corp.(NasdaqCM:EBAC) added to NASDAQ Composite Index	19/05/21	CI
European Biotech Acquisition Corp. announced that it has received $4.55096 million in funding from Lsp Sponsor Ebac B.V.	02/05/21	CI
European Biotech Acquisition Corp. Appoints Mohammad Sohail Fazeli to the Board	18/03/21	CI
European Biotech Acquisition Corp. has completed an IPO in the amount of $120 million.	18/03/21	CI
European Biotech Acquisition Corp. has filed an IPO in the amount of $100 million.	17/02/21	CI
European Biotech Acquisition Corp. announced that it expects to receive $4 million in funding from Lsp Sponsor Ebac B.V.	16/02/21	CI

European Biotech Acquisition Corp is a blanc check company based in the Netherlands. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The Company intends to primarily seek to identify a company within the European life sciences industry. The aim of the Company is investments in therapeutic drug candidates in clinical development across a range of therapeutic areas, including oncology, diabetes, cardiology, central nervous system (CNS) and orphan diseases.

Sector

More about the company